Forde, S; Matthews, JD; Jahangiri, L; Lee, LC; Prokoph, N; Malcolm, TIM; Giger, OT; Bell, N; Blair, H; O'Marcaigh, A; Smith, O; Kenner, L; Bomken, S; Burke, GAA; Turner, SD
Paediatric Burkitt lymphoma patient-derived xenografts capture disease characteristics over time and are a model for therapy.
Br J Haematol. 2021 192 (2) 354-365.
Autor/innen der Vetmeduni Vienna:
Institut für Pathologie, Abteilung für Labortierpathologie
- Burkitt lymphoma (BL) accounts for almost two-thirds of all B-cell non-Hodgkin lymphoma (B-NHL) in children and adolescents and is characterised by a MYC translocation and rapid cell turnover. Intensive chemotherapeutic regimens have been developed in recent decades, including the lymphomes malins B (LMB) protocol, which have resulted in a survival rate in excess of 90%. Recent clinical trials have focused on immunochemotherapy, with the addition of rituximab to chemotherapeutic backbones, showing encouraging results. Despite these advances, relapse and refractory disease occurs in up to 10% of patients and salvage options for these carry a dismal prognosis. Efforts to better understand the molecular and functional characteristics driving relapse and refractory disease may help improve this prognosis. This study has established a paediatric BL patient-derived xenograft (PDX) resource which captures and maintains tumour heterogeneity, may be used to better characterise tumours and identify cell populations responsible for therapy resistance.© 2020 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.